Indications -- cardiovascular Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- cardiovascular

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	11/17/2003 1:45:58 PM
From: tuck	Read Replies (1) of 214

>>Enoximone, a type-III selective phosphodiesterase inhibitor, is a positive inotropic agent that increases the force of contraction of the heart. The intravenous formulation of enoximone, Perfan I.V., is used for the treatment of acute decompensated heart failure. We are evaluating enoximone capsules, the oral formulation of enoximone, in three Phase III clinical trials for the long-term treatment of advanced chronic heart failure. We expect these trials will be fully enrolled by the end of this year and, if the trials progress as planned, we expect the patients will have completed treatment by the end of 2004. We believe that enoximone capsules have the potential to alleviate symptoms, reduce hospitalizations and improve quality of life for patients with advanced chronic heart failure. << This is from Myogen's (MYOG) S-1. Can anyone tell me when results might be expected from this trial assuming it enrolls as planned? Are chances high for success given it's simply an oral formulation of Perfan? Feel free to respond by PM or on the MYOG thread if it would clutter this one. Subject 54233 TIA & Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next